Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Protein Kinase Inhibitors"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 37928
Tytuł:
Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.
Autorzy:
Lei J; Guizhou Medical University, Guiyang, China.
Yan T; Comprehensive Liver Cancer Center, The 5th Medical Center of the PLA General Hospital, Beijing, China.
Zhang L; Comprehensive Liver Cancer Center, The 5th Medical Center of the PLA General Hospital, Beijing, China.
Chen B; Peking University 302 Clinical Medical School, Beijing, China.
Cheng J; Comprehensive Liver Cancer Center, The 5th Medical Center of the PLA General Hospital, Beijing, China.
Gao X; Guizhou Medical University, Guiyang, China.; Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Liu Z; Peking University 302 Clinical Medical School, Beijing, China.
Li Y; Comprehensive Liver Cancer Center, The 5th Medical Center of the PLA General Hospital, Beijing, China.
Zuo S; Guizhou Medical University, Guiyang, China. .; Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China. .
Lu Y; Guizhou Medical University, Guiyang, China. .; Comprehensive Liver Cancer Center, The 5th Medical Center of the PLA General Hospital, Beijing, China. .; Guangdong Key Laboratory of Epigenetics, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, China. .
Pokaż więcej
Źródło:
Hepatology international [Hepatol Int] 2023 Apr; Vol. 17 (2), pp. 281-290. Date of Electronic Publication: 2022 Dec 29.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/pathology
Carcinoma, Hepatocellular*/virology
Hepatitis B*/physiopathology
Hepatitis B*/virology
Immune Checkpoint Inhibitors*/pharmacology
Immune Checkpoint Inhibitors*/therapeutic use
Liver Neoplasms*/drug therapy
Liver Neoplasms*/pathology
Liver Neoplasms*/virology
Tyrosine Protein Kinase Inhibitors*/pharmacology
Tyrosine Protein Kinase Inhibitors*/therapeutic use
Virus Activation*/drug effects
Humans ; Hepatitis B virus/drug effects ; Hepatitis B virus/physiology ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Retrospective Studies ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy.
Autorzy:
Rodriguez J; Graduate Program in Mathematical, Computational and Systems Biology, University of California, Irvine, Irvine, United States.; Center for Complex Biological Systems, University of California, Irvine, Irvine, United States.
Iniguez A; Graduate Program in Mathematical, Computational and Systems Biology, University of California, Irvine, Irvine, United States.; Center for Complex Biological Systems, University of California, Irvine, Irvine, United States.
Jena N; Department of Medicine, University of California, Irvine, Irvine, United States.
Tata P; Department of Medicine, University of California, Irvine, Irvine, United States.
Liu ZY; Department of Medicine, University of California, Irvine, Irvine, United States.
Lander AD; Center for Complex Biological Systems, University of California, Irvine, Irvine, United States.; Department of Developmental and Cell Biology, University of California, Irvine, Irvine, United States.; Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, United States.; Department of Biomedical Engineering, University of California, Irvine, Irvine, United States.
Lowengrub J; Center for Complex Biological Systems, University of California, Irvine, Irvine, United States.; Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, United States.; Department of Biomedical Engineering, University of California, Irvine, Irvine, United States.; Department of Mathematics, University of California, Irvine, Irvine, United States.
Van Etten RA; Center for Complex Biological Systems, University of California, Irvine, Irvine, United States.; Department of Medicine, University of California, Irvine, Irvine, United States.; Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, United States.
Pokaż więcej
Źródło:
ELife [Elife] 2023 Apr 28; Vol. 12. Date of Electronic Publication: 2023 Apr 28.
Typ publikacji:
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
MeSH Terms:
Tyrosine Protein Kinase Inhibitors*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics
Mice ; Animals ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Drug Resistance, Neoplasm ; Myelopoiesis ; Fusion Proteins, bcr-abl/genetics ; Fusion Proteins, bcr-abl/pharmacology ; Mice, Transgenic
Czasopismo naukowe
Szczegóły
Tytuł:
Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for de novo lymphoid blast phase-chronic myeloid leukemia.
Autorzy:
Yang Z; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China.
Liu C; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China.
Hu Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China.
Liu H; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China.
Li J; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China.
Wu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China.
Liu Q; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China.
Zheng Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China.
Huang P; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China.
Wang Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China. Electronic address: .
Pokaż więcej
Źródło:
Leukemia research [Leuk Res] 2023 Apr; Vol. 127, pp. 107039. Date of Electronic Publication: 2023 Feb 12.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Blast Crisis*/drug therapy
Tyrosine Protein Kinase Inhibitors*
Humans ; Azacitidine/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Fusion Proteins, bcr-abl ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/pharmacology
Raport
Szczegóły
Tytuł:
Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies.
Autorzy:
Fauziya; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
Gupta A; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
Nadaf A; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
Ahmad S; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
Hasan N; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
Imran M; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
Sahebkar A; Applied Biomedical Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran.
Jain GK; Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, India.
Kesharwani P; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India. .; Center for Transdisciplinary Research, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Science, Chennai, India. .
Ahmad FJ; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India. .
Pokaż więcej
Źródło:
Medical oncology (Northwood, London, England) [Med Oncol] 2023 May 10; Vol. 40 (6), pp. 173. Date of Electronic Publication: 2023 May 10.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Tyrosine Protein Kinase Inhibitors*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Humans ; Dasatinib/pharmacology ; Dasatinib/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Imatinib Mesylate/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
Long-Term Outcomes with Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients.
Autorzy:
Towachiraporna S; Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Punnachet T; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Hantrakun N; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Piriyakhuntorn P; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Rattanathammethee T; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Hantrakool S; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Chai-Adisaksopha C; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Rattarittamrong E; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Norasetthada L; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Tantiworawit A; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Pokaż więcej
Źródło:
Asian Pacific journal of cancer prevention : APJCP [Asian Pac J Cancer Prev] 2023 May 01; Vol. 24 (5), pp. 1513-1520. Date of Electronic Publication: 2023 May 01.
Typ publikacji:
Journal Article
MeSH Terms:
Tyrosine Protein Kinase Inhibitors*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/diagnosis
Humans ; Female ; Adult ; Middle Aged ; Male ; Imatinib Mesylate/therapeutic use ; Dasatinib/therapeutic use ; Protein Kinase Inhibitors/therapeutic use ; Treatment Outcome ; Retrospective Studies
Czasopismo naukowe
Szczegóły
Tytuł:
Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor.
Autorzy:
Bidikian A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2023 Apr; Vol. 98 (4), pp. 639-644. Date of Electronic Publication: 2023 Jan 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Tyrosine Protein Kinase Inhibitors*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics
Humans ; Treatment Outcome ; Fusion Proteins, bcr-abl/genetics ; Protein Kinase Inhibitors
Czasopismo naukowe
Szczegóły
Tytuł:
Receptor tyrosine kinase inhibitors in cancer.
Autorzy:
Ebrahimi N; Genetics Division, Department of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Iran.
Fardi E; Medical Branch, Islamic Azad University of Tehran, Tehran, Iran.
Ghaderi H; Laboratory of Regenerative and Medical Innovation, Pasteur Institute of Iran, Tehran, Iran.
Palizdar S; Division of Microbiology, Faculty of Basic Sciences, Islamic Azad University of Tehran East Branch, Tehran, Iran.
Khorram R; Bone and Joint Diseases Research Center, Department of Orthopedic Surgery, Shiraz University of Medical Sciences, Shiraz, Iran.
Vafadar R; Department of Orthopeadic Surgery, Kerman University of Medical Sciences, Kerman, Iran.
Ghanaatian M; Master 1 Bio-Santé-Parcours Toulouse Graduate School of Cancer, Ageing and Rejuvenation (CARe), Université Toulouse III-Paul Sabatier, Toulouse, France.
Rezaei-Tazangi F; Department of Anatomy, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran.
Baziyar P; Department of Molecular and Cell Biology, Faculty of Basic Science, Uinversity of Mazandaran, Babolsar, Iran.
Ahmadi A; Department of Biological Science and Technology, Faculty of Nano and Bio Science and Technology, Persian Gulf University, Bushehr, 75169, Iran. .
Hamblin MR; Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein, 2028, South Africa. .
Aref AR; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA. .; Translational Medicine Group, Xsphera Biosciences, 6 Tide Street, Boston, MA, 02210, USA. .
Pokaż więcej
Źródło:
Cellular and molecular life sciences : CMLS [Cell Mol Life Sci] 2023 Mar 22; Vol. 80 (4), pp. 104. Date of Electronic Publication: 2023 Mar 22.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Tyrosine Protein Kinase Inhibitors*
Neoplasms*/drug therapy
Neoplasms*/metabolism
Humans ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/chemistry ; Receptor Protein-Tyrosine Kinases/metabolism ; Signal Transduction
Czasopismo naukowe
Szczegóły
Tytuł:
EVI1 upregulates PTGS1 (COX1) and decreases the action of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia cells.
Autorzy:
Vinothkumar K; Cancer Biology Group, Institute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, India.
Chanda S; Cancer Biology Group, Institute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, India.; Regional Centre for Biotechnology, Faridabad, Haryana, India.
Singh VK; Cancer Biology Group, Institute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, India.
Biswas S; Sparsh Hospital and Critical Care, Bhubaneswar, India.
Mohapatra S; Department of Medical Oncology/Hematology, All India Institute of Medical Sciences, Bhubaneswar, India.
Biswas G; Sparsh Hospital and Critical Care, Bhubaneswar, India.
Chakraborty S; Cancer Biology Group, Institute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, India. soumen_.; Regional Centre for Biotechnology, Faridabad, Haryana, India. soumen_.
Pokaż więcej
Źródło:
International journal of hematology [Int J Hematol] 2023 Jan; Vol. 117 (1), pp. 110-120. Date of Electronic Publication: 2022 Oct 25.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/metabolism
Tyrosine Protein Kinase Inhibitors*
Humans ; Apoptosis ; Cyclooxygenase 1/pharmacology ; Cyclooxygenase 1/therapeutic use ; Drug Resistance, Neoplasm/genetics ; Fusion Proteins, bcr-abl ; Imatinib Mesylate/pharmacology ; Imatinib Mesylate/therapeutic use ; K562 Cells ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics.
Autorzy:
Kozaki R; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan.
Yasuhiro T; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan.
Kato H; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan.
Murai J; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan.
Hotta S; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan.
Ariza Y; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan.
Sakai S; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan.
Fujikawa R; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan.
Yoshida T; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Mar 10; Vol. 18 (3), pp. e0282166. Date of Electronic Publication: 2023 Mar 10 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Tyrosine Protein Kinase Inhibitors*
Lymphoma, Large B-Cell, Diffuse*/pathology
Humans ; Agammaglobulinaemia Tyrosine Kinase ; Transcriptome ; Proto-Oncogene Proteins c-akt/metabolism ; Leukocytes, Mononuclear/metabolism ; Protein Kinase Inhibitors/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML.
Autorzy:
Ono T; Department of Transfusion and Cell Therapy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Takahashi N; Department of Hematology, Nephrology, and Rheumatology, Akita University School of Medicine, Akita, Japan.
Kizaki M; Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Kawaguchi T; Department of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan.
Suzuki R; Department of Hematology and Oncology, Faculty of Medicine, Shimane University, Izumo, Japan.
Yamamoto K; Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
Ohnishi K; Shubun University Faculty of Medical Sciences, Ichinomiya, Japan.
Naoe T; National Hospital Organization, Nagoya Medical Center, Nagoya, Japan.
Matsumura I; Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Pokaż więcej
Źródło:
Cancer science [Cancer Sci] 2023 Mar; Vol. 114 (3), pp. 995-1006. Date of Electronic Publication: 2022 Nov 23.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Tyrosine Protein Kinase Inhibitors*
Aged ; Humans ; Fusion Proteins, bcr-abl ; Imatinib Mesylate/therapeutic use ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.
Autorzy:
Lu CW; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Pang JS; Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Linkou, Taiwan.
Ko YS; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Cardiovascular Division, Chang Gung Memorial Hospital, Linkou, Taiwan.; Microscope Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan.
Chang CJ; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.; Allergology Consortium, Xiamen Chang Gung Hospital, Xiamen, Fujian, China.; Medical Research Center, Xiamen Chang Gung Hospital, Xiamen, Fujian, China.; School of Medicine, Huaqiao University, Quanzhou, Fujian, China.
Wang CW; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.; Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan.; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China.
Chen WT; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China.
Chen CB; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.; Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan.; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China.; Chang Gung Immunology Consortium, Chang Gung University, Taiwan.; Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan.
Hui RC; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Hung SI; Allergology Consortium, Xiamen Chang Gung Hospital, Xiamen, Fujian, China.; Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Lu LY; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Lu KL; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.
Wang CL; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Division of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.
Wu CE; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.; Division of Hematology-Oncology, Chang Gung Memorial Hospital, Linkou, Taiwan.
Hsu PC; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Division of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.
Fang YF; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Division of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.
Li SH; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Division of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.
Ko HW; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Division of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.
Tseng LC; Department of Oncology Case Management, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Shih FY; Department of Oncology Case Management, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Chen MJ; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.
Chung WH; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Pokaż więcej
Źródło:
Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2023 Feb; Vol. 37 (2), pp. 328-339. Date of Electronic Publication: 2022 Nov 16.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma of Lung*/drug therapy
Exanthema*/chemically induced
Exanthema*/drug therapy
Lung Neoplasms*/drug therapy
Lung Neoplasms*/pathology
Tyrosine Protein Kinase Inhibitors*/adverse effects
Zinc*/metabolism
Animals ; Mice ; Rats ; ErbB Receptors ; Erlotinib Hydrochloride/adverse effects ; Mutation ; Protein Kinase Inhibitors/adverse effects ; Retrospective Studies
Czasopismo naukowe
Szczegóły
Tytuł:
Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Autorzy:
Umezawa Y; Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX, 77030, USA. .
Pokaż więcej
Źródło:
International journal of hematology [Int J Hematol] 2023 Jan; Vol. 117 (1), pp. 24-29. Date of Electronic Publication: 2022 Sep 10.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Tyrosine Protein Kinase Inhibitors*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Humans ; Protein Kinase Inhibitors/adverse effects ; Molecular Targeted Therapy
Czasopismo naukowe
Szczegóły
Tytuł:
Additional Chromosomal Abnormalities in Chronic Myeloid Leukemia Patient Treated with First-Line Tyrosine Kinase Inhibitor Therapy: Good or Poor Prognosis?
Autorzy:
Rajabto W; Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia. .
Joenputri N
Pokaż więcej
Źródło:
Acta medica Indonesiana [Acta Med Indones] 2022 Oct; Vol. 54 (4), pp. 603-606.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Tyrosine Protein Kinase Inhibitors*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics
Male ; Humans ; Adult ; Protein Kinase Inhibitors/therapeutic use ; Chromosome Aberrations/chemically induced ; Chronic Disease ; Prognosis
Czasopismo naukowe
Szczegóły
Tytuł:
EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study.
Autorzy:
Helland Å; Department of Cancer Genetics, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway; Department of Oncology, Oslo University Hospital, Norway.
Andersen KK; Medical, Biopharmaceuticals, AstraZeneca Nordic, Copenhagen, Denmark.
Myklebust TÅ; Department of Research and Innovation, Møre and Romsdal Hospital Trust, Ålesund, Norway; Department of Registration, Cancer Registry of Norway, Oslo, Norway.
Johannesen TB; Department of Registration, Cancer Registry of Norway, Oslo, Norway.
Aarøe J; Medical, Biopharmaceuticals, AstraZeneca of Nordic, Oslo, Norway.
Enerly E; Department of Research, Cancer Registry of Norway, Oslo, Norway. Electronic address: .
Pokaż więcej
Źródło:
Cancer treatment and research communications [Cancer Treat Res Commun] 2022; Vol. 33, pp. 100636. Date of Electronic Publication: 2022 Sep 16.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
ErbB Receptors*/genetics
Tyrosine Protein Kinase Inhibitors*/pharmacology
Tyrosine Protein Kinase Inhibitors*/therapeutic use
Genetic Testing*/methods
Genetic Testing*/trends
Female ; Humans ; Male ; Cohort Studies ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Retrospective Studies ; Norway/epidemiology
Czasopismo naukowe
Szczegóły
Tytuł:
Aurora A kinase inhibition compromises its antitumor efficacy by elevating PD-L1 expression.
Autorzy:
Wang X; Key Laboratory of Metabolism and Molecular Medicine, the Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Huang J; Drug Discovery and Design Center, the Center for Chemical Biology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; China University of Chinese Academy of Sciences, Beijing, China.
Liu F; Department of General Surgery and.
Yu Q; Key Laboratory of Metabolism and Molecular Medicine, the Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Wang R; Key Laboratory of Metabolism and Molecular Medicine, the Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Wang J; Key Laboratory of Metabolism and Molecular Medicine, the Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Zhu Z; Key Laboratory of Metabolism and Molecular Medicine, the Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Yu J; Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Hou J; Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Shim JS; Department of Pharmaceutical Sciences and Cancer Centre, Faculty of Health Science, University of Macau, Taipa, Macau SAR, China.
Jiang W; Key Laboratory of Metabolism and Molecular Medicine, the Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Li Z; Key Laboratory of Metabolism and Molecular Medicine, the Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Zhang Y; Drug Discovery and Design Center, the Center for Chemical Biology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; China University of Chinese Academy of Sciences, Beijing, China.
Dang Y; Key Laboratory of Metabolism and Molecular Medicine, the Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.; Center for Novel Target and Therapeutic Intervention, Institute of Life Sciences, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China.
Pokaż więcej
Źródło:
The Journal of clinical investigation [J Clin Invest] 2023 May 01; Vol. 133 (9). Date of Electronic Publication: 2023 May 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Aurora Kinase A*/genetics
Aurora Kinase A*/metabolism
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Animals ; Mice ; B7-H1 Antigen/genetics ; Cell Line, Tumor ; Nucleotidyltransferases ; Humans
Czasopismo naukowe
Szczegóły
Tytuł:
Capturing Differences in the Regulation of LRRK2 Dynamics and Conformational States by Small Molecule Kinase Inhibitors.
Autorzy:
Weng JH; Department of Pharmacology, University of California, San Diego, California 92093, United States.
Ma W; Department of Chemistry and Biochemistry, University of California, San Diego, California 92093, United States.
Wu J; Department of Pharmacology, University of California, San Diego, California 92093, United States.
Sharma PK; Department of Pharmacology, University of California, San Diego, California 92093, United States.
Silletti S; Department of Chemistry and Biochemistry, University of California, San Diego, California 92093, United States.
McCammon JA; Department of Pharmacology, University of California, San Diego, California 92093, United States.; Department of Chemistry and Biochemistry, University of California, San Diego, California 92093, United States.
Taylor S; Department of Pharmacology, University of California, San Diego, California 92093, United States.; Department of Chemistry and Biochemistry, University of California, San Diego, California 92093, United States.
Pokaż więcej
Źródło:
ACS chemical biology [ACS Chem Biol] 2023 Apr 21; Vol. 18 (4), pp. 810-821. Date of Electronic Publication: 2023 Apr 12.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2*/chemistry
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2*/drug effects
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2*/metabolism
Parkinson Disease*/drug therapy
Protein Kinase Inhibitors*/chemistry
Protein Kinase Inhibitors*/pharmacology
Humans ; Molecular Conformation ; Mutation ; Phosphorylation
Czasopismo naukowe
Szczegóły
Tytuł:
Design, synthesis and bioactivity evaluation of a series of quinazolinone derivatives as potent PI3Kγ antagonist.
Autorzy:
Liang Y; Guangdong Provincial Key Laboratory of New Drug Screening and Guangzhou Key Laboratory of Drug Research for Emerging Virus Prevention and Treatment, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Zheng Y; Guangdong Provincial Key Laboratory of New Drug Screening and Guangzhou Key Laboratory of Drug Research for Emerging Virus Prevention and Treatment, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Yang J; Guangdong Provincial Key Laboratory of New Drug Screening and Guangzhou Key Laboratory of Drug Research for Emerging Virus Prevention and Treatment, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Ke J; Guangdong Provincial Key Laboratory of New Drug Screening and Guangzhou Key Laboratory of Drug Research for Emerging Virus Prevention and Treatment, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Cheng K; Guangdong Provincial Key Laboratory of New Drug Screening and Guangzhou Key Laboratory of Drug Research for Emerging Virus Prevention and Treatment, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China. Electronic address: .
Pokaż więcej
Źródło:
Bioorganic & medicinal chemistry [Bioorg Med Chem] 2023 Apr 15; Vol. 84, pp. 117261. Date of Electronic Publication: 2023 Mar 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/chemistry
Leukemia*
Neoplasms*
Protein Kinase Inhibitors*/chemistry
Protein Kinase Inhibitors*/pharmacology
Quinazolinones*/chemistry
Quinazolinones*/pharmacology
Animals ; Humans ; Mice ; Cell Proliferation ; Drug Design ; Phosphatidylinositol 3-Kinases/metabolism ; Structure-Activity Relationship ; Class Ib Phosphatidylinositol 3-Kinase
Czasopismo naukowe
Szczegóły
Tytuł:
Design, Synthesis and Antitumor Activity of FAK/PLK1 Dual Inhibitors with Quinazolinone as the Skeleton.
Autorzy:
Sun J; School of Biological & Chemical Engineering, Zhejiang University of Science & Technology, Hangzhou, 310023, P. R. China.
Fang ZY; School of Biological & Chemical Engineering, Zhejiang University of Science & Technology, Hangzhou, 310023, P. R. China.
Tao YN; School of Biological & Chemical Engineering, Zhejiang University of Science & Technology, Hangzhou, 310023, P. R. China.
Zhang YH; School of Biological & Chemical Engineering, Zhejiang University of Science & Technology, Hangzhou, 310023, P. R. China.
Zhang Y; School of Biological & Chemical Engineering, Zhejiang University of Science & Technology, Hangzhou, 310023, P. R. China.
Sun HY; School of Biological & Chemical Engineering, Zhejiang University of Science & Technology, Hangzhou, 310023, P. R. China.
Zhou Y; Zhejiang Engineering Research Center for Biomedical Materials, Cixi Institute of Biomedical Engineering, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo, 315300, P. R. China.
Wu YF; School of Biological & Chemical Engineering, Zhejiang University of Science & Technology, Hangzhou, 310023, P. R. China.
Pokaż więcej
Źródło:
Chemistry & biodiversity [Chem Biodivers] 2023 Apr; Vol. 20 (4), pp. e202300146. Date of Electronic Publication: 2023 Mar 15.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/chemistry
Protein Kinase Inhibitors*/chemistry
Protein Kinase Inhibitors*/pharmacology
Quinazolinones*/chemistry
Quinazolinones*/pharmacology
Cell Line ; Cell Proliferation ; Drug Design ; Drug Screening Assays, Antitumor ; Magnetic Resonance Spectroscopy ; Molecular Docking Simulation ; Skeleton ; Structure-Activity Relationship ; Focal Adhesion Kinase 1/antagonists & inhibitors
Czasopismo naukowe
Szczegóły
Tytuł:
Computational analysis of protein-ligand interaction by targeting a cell cycle restrainer.
Autorzy:
Singh R; Structural Bioinformatics Lab, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Palampur, HP 176061, India; Biotechnology Division, CSIR-IHBT, Palampur, HP 176061, India; Academy of Scientific & Innovative Research (AcSIR), Ghaziabad 201002, India.
Purohit R; Structural Bioinformatics Lab, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Palampur, HP 176061, India; Biotechnology Division, CSIR-IHBT, Palampur, HP 176061, India; Academy of Scientific & Innovative Research (AcSIR), Ghaziabad 201002, India. Electronic address: .
Pokaż więcej
Źródło:
Computer methods and programs in biomedicine [Comput Methods Programs Biomed] 2023 Apr; Vol. 231, pp. 107367. Date of Electronic Publication: 2023 Jan 24.
Typ publikacji:
Journal Article
MeSH Terms:
Protein Kinase Inhibitors*/chemistry
Protein Kinase Inhibitors*/pharmacology
Molecular Dynamics Simulation*
Ligands ; Cell Cycle ; Cell Proliferation
Czasopismo naukowe
Szczegóły
Tytuł:
A novel CDK8 inhibitor with poly-substituted pyridine core: Discovery and anti-inflammatory activity evaluation in vivo.
Autorzy:
Chen X; School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei 230032, PR China.
Yan Y; School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei 230032, PR China.
Cheng X; School of Pharmacy, BengBu Medical College, BengBu 233030, PR China.
Zhang Z; School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei 230032, PR China.
He C; School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei 230032, PR China.
Wu D; School of Biological Engineering, Hefei Technology College, Hefei 238000, PR China.
Zhao D; Department of Respiratory and Critical Care Medicine, The Second Hospital, Anhui Medical University, Hefei 230032, PR China. Electronic address: .
Liu X; School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei 230032, PR China. Electronic address: .
Pokaż więcej
Źródło:
Bioorganic chemistry [Bioorg Chem] 2023 Apr; Vol. 133, pp. 106402. Date of Electronic Publication: 2023 Feb 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Interleukin-10*/metabolism
Protein Kinase Inhibitors*/chemistry
Protein Kinase Inhibitors*/pharmacology
Animals ; Cyclin-Dependent Kinase 8/antagonists & inhibitors ; Pyridines/pharmacology ; Signal Transduction ; Transcription Factor AP-1
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 37928

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies